Mayo Clinic Laboratories > Therapeutics > Drug class testing

Drug class testing

Focused analysis to detect and monitor

To help clinicians accurately detect prescription drug, illicit substance, or alcohol use by their patients, we offer a complete menu of targeted testing by drug class. Developed by our clinical and forensic toxicology experts, these assays use precision and emerging techniques to identify parent drugs and metabolites, and in the case of ethanol biomarkers, to assess use.

27

27 benzodiazepines detected in our targeted screening panel

33

33 opioids detected in our targeted screening panel

10

10 stimulants and PCP detected in our targeted screening panel

Testing menu

Benzodiazepines Benzodiazepines
BenzodiazepineS

Using high-resolution mass spectrometry, our targeted benzodiazepine screening assay identifies 27 benzodiazepines and metabolites in urine, reducing the need for additional confirmatory testing.

Ethanol Ethanol
Ethanol

Our menu of direct ethanol biomarker testing provides heightened sensitivity and specificity to accurately assess alcohol use and alcohol use disorder.

Marijuana Marijuana
Marijuana

We offer a comprehensive portfolio of marijuana testing, including a unique evaluation to accurately characterize marijuana through identification of both delta-8 and delta-9 carboxy THC metabolites.

Nicotine Nicotine
Nicotine

Testing can help physicians recognize and treat nicotine dependence. We offer serum and urine testing to identify and monitor nicotine use as part of a patient’s treatment plan.

Opioids Opioids
OpioidS

Our targeted, high-resolution mass spectrometry screening assay does not hydrolyze the urine sample, allowing for both the parent and metabolites of 33 different opioids to be detected.

Stimulants Stimulants
StimulantS

Our targeted, high-resolution mass spectrometry screening panel identifies and confirms the presence of 10 stimulants and phencyclidine (PCP) with a single test.

News and updates

The latest

Testing aids nicotine-use cessation: Paul Jannetto, Ph.D.

Tobacco use is the leading cause of preventable death in the United States. In this test-specific episode of the "Answers From the Lab" podcast, Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' nicotine testing benefits patients in smoking cessation programs and other settings.

Learn more
High-Resolution Targeted Benzodiazepine Screen

In this “Hot Topic,” Paul Jannetto, Ph.D., highlights Mayo Clinic’s targeted benzodiazepine assay and discusses the advantages and limitations of various urine-screening assays as well as quantitative confirmatory testing to determine compliance to benzodiazepine therapy.

Accurately characterize marijuana use through urine THC testing

Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories’ new marijuana monitoring evaluation, which identifies metabolites of both delta-9 tetrahydrocannabinol (THC) and delta-8 THC to accurately identify and characterize patients’ marijuana use.

The ABCs of CBD

In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Paul Jannetto, Ph.D., associate professor of laboratory medicine and pathology at Mayo Clinic, and discusses how CBD can affect your health, what the medical benefits are, and its impact on urine drugs of abuse testing.

Direct Ethanol Biomarker Testing: PETH

Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.

Weeding Through the Information: Interpreting Laboratory Tests to Determine New vs. Residual Use of Marijuana

In this month's "Hot Topic," Paul Jannetto, Ph.D., identifies how to determine new vs. residual use of marijuana in a patient, and teaches how to calculate the carboxy-tetrahydrocannabinol (carboxy-THC) to creatinine ratio along with a decision ratio by demonstrating its clinical utility via case study.

New High-Resolution Targeted Opioid Screen: Superior Sensitivity and Specificity to Evaluate Adherence to Prescribed Opioid Therapy

In this month’s “Hot Topic,” Paul Jannetto, Ph.D., discusses the high-resolution targeted opioid screening test from Mayo Clinic Laboratories, which offers sensitivity and specificity for use in the monitoring and management of patients who are prescribed opioid pain-relieving medication.

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.